



## Reena Thomas, MD PhD

- Clinical Associate Professor, Neurology & Neurological Sciences
- Clinical Associate Professor (By courtesy), Neurosurgery

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center Neuro Oncology**

875 Blake Wilbur Dr Rm CC2221

Stanford, CA 94305

**Tel** (650) 498-6000

**Fax** (650) 724-3556

### ACADEMIC CONTACT INFORMATION

- **Administrative Contact**

**Tel** (650) 725-8630

### Bio

---

#### BIO

Dr. Reena Thomas, MD, PhD, is a Clinical Associate Professor in Neuro Oncology at Stanford Medicine leading a translational research team in immune-based therapy for cancer. Holding dual degrees in medicine and molecular immunology, Dr. Thomas has worked for more than two decades to integrate clinical expertise with a deep understanding of cellular immunotherapy mechanisms and burgeoning technologies such as CAR-T (Chimeric Antigen Receptor T lymphocyte) cell therapy. These scientific advancements center foremost on improving outcomes for her patients with central nervous system tumors and all those impacted by neurologic complications of cancer.

As a leader in translational research, Dr. Thomas recently secured a \$12 million award to spearhead CAR-T cell therapy innovation for glioblastoma brain tumors, working with her team to revolutionize treatment possibilities and outcomes for patients. She brings more than a decade of experience serving as principal investigator on several NIH funded research programs and trials including a study that established the new standard of care for using checkpoint inhibitor immune therapy for melanoma brain metastasis. Her dedication to advancing medical knowledge is grounded in providing hope to families and bringing her diverse lived experience and scientific accomplishments to bear in the fight against cancer.

Beyond research, Dr. Thomas is nationally recognized for her excellence in medical education, for her role in shaping the next generation of healthcare professionals in her tenure as Fellowship Program Director of Neuro Oncology and subsequently as Associate Dean of Diversity in Medical Education at Stanford Medicine. Her commitment to fostering diversity and inclusion in medicine is evident through her advocacy for health equity, striving to dismantle systemic barriers and ensure equitable access to care for all patients.

Dr. Thomas continues to lead in education program development, principally via a transformative \$25 million gift fueling the REACH initiative (Racial Equity to Advance Community Health). This initiative reflects Dr. Thomas' outcome focused approach to addressing health disparities and to promoting community well-being through innovation and collaborative solutions.

#### CLINICAL FOCUS

- Neuro Oncology

- Neurology
- Immunotherapy
- Immuno Oncology
- Primary Brain Tumors
- Metastatic Cancer to CNS
- Neuro-Oncology

### **ACADEMIC APPOINTMENTS**

- Clinical Associate Professor, Neurology & Neurological Sciences
- Clinical Associate Professor (By courtesy), Neurosurgery
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

### **ADMINISTRATIVE APPOINTMENTS**

- Adult Neuro Oncology Fellowship Program Director, Stanford Hospital, (2014-2021)
- Education Chief of Neuro Oncology, Department of Neurology, (2017-2020)
- Director of Diversity and Inclusion, Department of Neurology, (2017-2021)
- Associate Dean, Diversity in Medical Education, Stanford School of Medicine, (2020- present)
- Vice Chair, Diversity and Inclusion, Department of Neurology, (2021- present)

### **HONORS AND AWARDS**

- Mentor of the Year, 1st Gen Mentorship Program, Stanford School of Medicine (November 2018)
- Graduating Resident Teaching Award, Stanford Neurology (July 2013)
- Silicon Valley Top 40 under 40, Silicon Valley Business Journal (December 2014)
- Principal Investigator of SPARK Grant, Stanford University (2015-2018)
- Stanford Faculty Development Grant, Hispanic Center of Excellence (2015, 2018)

### **BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS**

- Member, American Academy of Neurology (2010 - present)
- Member, Society for Neuro Oncology (2011 - present)
- Member, Stanford Society of Physician Scholars (2011 - present)
- Board Certified, American Board of Psychiatry and Neurology (2014 - present)
- Member, American Society of Clinical Oncology (2015 - present)

### **PROFESSIONAL EDUCATION**

- Internship: Georgetown University School of Medicine (2010) DC
- Medical Education: Georgetown University School of Medicine (2009) DC
- Fellowship: Stanford University School of Medicine (2014) CA
- BA, Cornell University , Biology; Neurobiology and Behavior (2002)
- PhD, City of Hope Graduate School of Biological Sciences, City of Hope Cancer Center , Molecular Immunology (2006)
- Residency: Stanford University School of Medicine (2013) CA
- Board Certification: Neurology, American Board of Psychiatry and Neurology (2014)

## COMMUNITY AND INTERNATIONAL WORK

- Faculty Mentor

## LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>
- Stanford Neuro Oncology: <http://med.stanford.edu/neurology/divisions/neurooncology.html>
- Office of Diversity in Medical Education: <https://med.stanford.edu/coe.html>

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

- Neuro Oncology Immunotherapy
- Health Equity
- Medical Education

### CLINICAL TRIALS

- B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme, Recruiting
- Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery, Recruiting
- Study Assessing QBS72S For Treating Brain Metastases, Recruiting
- [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers, Not Recruiting
- A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM), Not Recruiting
- A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE), Not Recruiting
- A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide, Not Recruiting
- An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself, Not Recruiting
- BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab, Not Recruiting
- Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors, Not Recruiting
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM), Not Recruiting
- Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases, Not Recruiting
- ONC201 in Adults With Recurrent H3 K27M-mutant Glioma, Not Recruiting
- Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma, Not Recruiting
- Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies, Not Recruiting
- The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma, Not Recruiting

## Teaching

---

### COURSES

#### 2020-21

- Medical Spanish: INDE 274 (Win)

## STANFORD ADVISEES

### Med Scholar Project Advisor

Akshay Swaminathan

## GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Oncology (Fellowship Program)

## Publications

---

### PUBLICATIONS

- **Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma.** *The neuroradiology journal*  
Iv, M., Naya, L., Sanan, S., Van Buskirk, S. L., Nagpal, S., Thomas, R. P., Recht, L. D., Patel, C. B.  
2023: 19714009231207083
- **Selective prediction for extracting unstructured clinical data.** *Journal of the American Medical Informatics Association : JAMIA*  
Swaminathan, A., Lopez, I., Wang, W., Srivastava, U., Tran, E., Bhargava-Shah, A., Wu, J. Y., Ren, A. L., Caoili, K., Bui, B., Alkhani, L., Lee, S., Mohit, et al  
2023
- **Patterns of Progression in Patients with Newly Diagnosed Glioblastoma Treated with 5 mm Margins on a Phase I/II Trial of 5 Fraction Stereotactic Radiosurgery with Concurrent and Adjuvant Temozolomide.** *Practical radiation oncology*  
Mendoza, M. G., Azoulay, M., Chang, S. D., Gibbs, I. C., Hancock, S. L., Pollom, E. L., Adler, J. R., Harraher, C., Li, G., Gephart, M. H., Nagpal, S., Thomas, R. P., Recht, et al  
2023
- **Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy.** *The Neurohospitalist*  
Satyanarayan, S., Spiegel, J., Hovsepian, D., Markert, M., Thomas, R., Muffly, L., Miklos, D., Graber, K., Scott, B. J.  
2023; 13 (1): 53-60
- **Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy** *NEUROHOSPITALIST*  
Satyanarayan, S., Spiegel, J., Hovsepian, D., Markert, M., Thomas, R., Muffly, L., Miklos, D., Graber, K., Scott, B. J.  
2022
- **Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.** *Practical radiation oncology*  
Halasz, L. M., Attia, A., Bradfield, L., Brat, D. J., Kirkpatrick, J. P., Laack, N. N., Lalani, N., Lebow, E. S., Liu, A. K., Niemeier, H. M., Palmer, J. D., Peters, K. B., Sheehan, et al  
2022
- **Modifiers of and Disparities in Palliative and Supportive Care Timing and Utilization among Neurosurgical Patients with Malignant Central Nervous System Tumors.** *Cancers*  
Jin, M. C., Hsin, G., Ratliff, J., Thomas, R., Zygourakis, C. C., Li, G., Wu, A.  
2022; 14 (10)
- **A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Beinat, C., Patel, C. B., Haywood, T., Murty, S., Naya, L., Castillo, J. B., Reyes, S. T., Phillips, M., Buccino, P., Shen, B., Park, J. H., Koran, M. E., Alam, et al  
2021
- **EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial.** *Theranostics*  
Zhou, Q., van den Berg, N. S., Rosenthal, E. L., Iv, M., Zhang, M., Vega Leonel, J. C., Walters, S., Nishio, N., Granucci, M., Raymundo, R., Yi, G., Vogel, H., Cayrol, et al  
2021; 11 (15): 7130-7143
- **Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).** *Neuro-oncology*

- Tawbi, H. A., Forsyth, P. A., Hodi, F. S., Lao, C. D., Moschos, S. J., Hamid, O., Atkins, M. B., Lewis, K., Thomas, R. P., Glaspy, J. A., Jang, S., Algazi, A. P., Khushalani, et al  
2021
- **Developing the Neurology Diversity Officer: A Roadmap for Academic Neurology Departments.** *Neurology*  
Mohile, N. A., Spector, A. R., Ebong, I. M., Flippen, C. 2., Gutierrez, C., Leacock, R. O., Marulanda-Londono, E., Mejia, N. I., Thomas, R., Hamilton, R. H.  
2021
  - **Outcomes From a Novel Graduate Medical Education Leadership Program in Advancing Diversity, Equity, and Inclusion** *Journal of Graduate Medical Education*  
Powell, C., Yemane, L., Brooks, M., Johnson, C., Alvarez, A., Bandstra, B., Caceres, W., Dierickx, Q., Thomas, R., Blankenburg, R.  
2021; 13 (6): 774–784
  - **Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.** *The Lancet. Oncology*  
Tawbi, H. A., Forsyth, P. A., Hodi, F. S., Algazi, A. P., Hamid, O., Lao, C. D., Moschos, S. J., Atkins, M. B., Lewis, K., Postow, M. A., Thomas, R. P., Glaspy, J., Jang, et al  
2021
  - **EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial** *Theranostics*  
Zhou, Q., van den Berg, N. S., Rosenthal, E. L., Iv, M., Zhang, M., Vega Leonel, J. C., Walters, S., Nishio, N., Granucci, M., Raymundo, R., Yi, G., Vogel, H., Cayrol, et al  
2021; 11 (15): 7130-7143
  - **Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy** *The Neurohospitalist*  
Reveron-Thornton, R., Scott, B. J., Post, D., Finley Caulfield, A., Werbaneth, K., Hovsepian, D. A., Spiegel, J., Miklos, D., Thomas, R. P., Patel, C. B.  
2021: 74-79
  - **Phase I study of BPM31510 and vitamin K in patients with high grade glioma recurrent after a bevacizumab-containing regimen.**  
Nagpal, S., Thomas, R., Bertrand, S., Yerraballa, H., Iv, M., Li, G., Klotz, A., Kiebish, M. A., Narain, N. R., Sarangarajan, R., Granger, E., Recht, L.  
AMER SOC CLINICAL ONCOLOGY.2020
  - **Neurological adverse effects due to programmed death 1 (PD-1) inhibitors.** *Journal of neuro-oncology*  
Shi, S., Jaoube, J. A., Kanwar, R., Jin, M. C., Amarin, A., Varanasi, V., Eisinger, E., Thomas, R., Moore, J. M.  
2020
  - **A Phase I/II Trial of 5-Fraction Stereotactic Radiosurgery with 5-mm Margins with Concurrent Temozolomide in Newly Diagnosed Glioblastoma: Primary Outcomes.** *Neuro-oncology*  
Azoulay, M. n., Chang, S. D., Gibbs, I. C., Hancock, S. L., Pollom, E. L., Harsh, G. R., Adler, J. R., Harrahar, C. n., Li, G. n., Hayden Gephart, M. n., Nagpal, S. n., Thomas, R. P., Recht, et al  
2020
  - **Intracranial Tumor Control Following Immune-Related Adverse Events and Discontinuation of Immunotherapy for Melanoma.** *World neurosurgery*  
Zhang, M. n., Rodrigues, A. J., Bhambhani, H. P., Fatemi, P. n., Pollom, E. L., Gibbs, I. C., Thomas, R. P., Soltys, S. G., Hancock, S. L., Chang, S. D., Reddy, S. A., Gephart, M. H., Li, et al  
2020
  - **Impact of the Patient Protection and Affordable Care Act on 1-year survival in glioblastoma patients.** *Neuro-oncology advances*  
Moghavem, N., Oh, D. L., Santiago-Rodriguez, E. J., Tate, W. J., Gomez, S. L., Thomas, R.  
2020; 2 (1): vdaa080
  - **Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma.** *Frontiers in oncology*  
Jin, M. C., Liu, E. K., Shi, S. n., Gibbs, I. C., Thomas, R. n., Recht, L. n., Soltys, S. G., Pollom, E. L., Chang, S. D., Hayden Gephart, M. n., Nagpal, S. n., Li, G. n.  
2020; 10: 337
  - **Macrophage exclusion after radiation therapy (MERT): A new and effective way to increase the therapeutic ratio of radiotherapy.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*  
Brown, J. M., Thomas, R., Nagpal, S., Recht, L.  
2019; 144: 159–64
  - **EVALUATION OF [18F]DASA-23 FOR NON-INVASIVE MEASUREMENT OF ABERRANTLY EXPRESSED PYRUVATE KINASE M2 IN GLIOMA: FIRST-IN-HUMAN STUDY**

- Patel, C., Beinat, C., Haywood, T., Murty, S., Xie, Y., Recht, L., Nagpal, S., Thomas, R., Khalighi, M., Gandhi, H., Holley, D., Gambhir, S.  
OXFORD UNIV PRESS INC.2019: 169
- **A PHASE 1 STUDY OF BPM31510 PLUS VITAMIN K IN SUBJECTS WITH HIGH-GRADE GLIOMA THAT HAS RECURRED ON A BEVACIZUMAB-CONTAINING REGIMEN**  
Recht, L., Thomas, R., Bertrand, S., Yerballa, P., Li, G., Iv, M., Narain, N., Sarangarajan, R., Granger, E., Nagpal, S.  
OXFORD UNIV PRESS INC.2019: 27
  - **Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)**  
Tawbi, H., Forsyth, P., Hodi, F., Lao, C., Moschos, S., Hamid, O., Atkins, M. B., Lewis, K., Thomas, R. P., Glaspy, J. A., Jang, S., Algazi, A., Khushalani, et al  
NATURE PUBLISHING GROUP.2019: 20
  - **Rooting out racial stereotypes in Neurology (R) A commentary on "Lucky and the root doctor" NEUROLOGY**  
Hamilton, R. H., McClean, J. C., Greicius, M. D., Gamaldo, C. E., Burrus, T. M., Charleston, L., Correa, D. J., Ebong, I. M., Hamilton, R., Lewis, S., Thomas, R. P., Vargas, A., Flippen, et al  
2019; 92 (22): 1029–32
  - **Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).**  
Tawbi, H., Forsyth, P. J., Hodi, F., Lao, C. D., Moschos, S. J., Hamid, O., Atkins, M. B., Lewis, K. D., Thomas, R., Glaspy, J. A., Jang, S., Algazi, A., Khushalani, et al  
AMER SOC CLINICAL ONCOLOGY.2019
  - **Rooting out racial stereotypes in Neurology: A commentary on "Lucky and the root doctor". Neurology**  
Hamilton, R. H., McClean, J. C., Greicius, M. D., Gamaldo, C. E., Burrus, T. M., Charleston, L. 4., Correa, D. J., Ebong, I. M., Hamilton, R., Lewis, S., Thomas, R. P., Vargas, A., Flippen, et al  
2019
  - **Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities PIGMENT CELL & MELANOMA RESEARCH**  
Eroglu, Z., Holmen, S. L., Chen, Q., Khushalani, N. I., Amaravadi, R., Thomas, R., Ahmed, K. A., Tawbi, H., Chandra, S., Markowitz, J., Smalley, I., Liu, J. C., Chen, et al  
2019; 32 (3): 458–69
  - **EEG Findings in Chimeric Antigen Receptor T-Cell (CAR-T) Related Encephalopathy Syndrome**  
Satyanarayan, S., Markert, M., Hovsepian, D., Post, D., Muffly, L., Miklos, D., Thomas, R., Scott, B.  
LIPPINCOTT WILLIAMS & WILKINS.2019
  - **Neurological Adverse Effects Due to Programmed Death (PD-1) Inhibitors**  
Shi, S., Kanwar, R., Varanasi, V., Eisinger, E., Thomas, R., Moore, J.  
LIPPINCOTT WILLIAMS & WILKINS.2019
  - **Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment cell & melanoma research**  
Eroglu, Z., Holmen, S. L., Chen, Q., Khushalani, N. I., Amaravadi, R., Thomas, R., Ahmed, K. A., Tawbi, H., Chandra, S., Markowitz, J., Smalley, I., Liu, J. K., Ann Chen, et al  
2019
  - **Nodular Leptomeningeal Disease - A Distinct Pattern of Recurrence After Post-Resection Stereotactic Radiosurgery for Brain Metastases: A Multi-Institutional Study of Inter-Observer Reliability. International journal of radiation oncology, biology, physics**  
Turner, B. E., Prabhu, R. S., Burri, S. H., Brown, P. D., Pollom, E. L., Milano, M. T., Weiss, S. E., Iv, M. n., Fischbein, N. n., Soliman, H. n., Lo, S. S., Chao, S. T., Cox, et al  
2019
  - **Perfusion MRI-Based Fractional Tumor Burden Differentiates between Tumor and Treatment Effect in Recurrent Glioblastomas and Informs Clinical Decision-Making. AJNR. American journal of neuroradiology**  
Iv, M. n., Liu, X. n., Lavezo, J. n., Gentles, A. J., Ghanem, R. n., Lummus, S. n., Born, D. E., Soltys, S. G., Nagpal, S. n., Thomas, R. n., Recht, L. n., Fischbein, N. n.  
2019
  - **Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research**

Thomas, R. P., Nagpal, S. n., Iv, M. n., Soltys, S. G., Bertrand, S. n., Pelpola, J. S., Ball, R. L., Yang, J. n., Sundaram, V. n., Lavezo, J. L., Born, D. E., Vogel, H. n., Brown, et al  
2019

- **Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.** *The New England journal of medicine*  
Tawbi, H. A., Forsyth, P. A., Algazi, A., Hamid, O., Hodi, F. S., Moschos, S. J., Khushalani, N. I., Lewis, K., Lao, C. D., Postow, M. A., Atkins, M. B., Ernstoff, M. S., Reardon, et al  
2018; 379 (8): 722–30
- **Quantification of Macrophages in High-Grade Gliomas by Using Ferumoxytol-enhanced MRI: A Pilot Study.** *Radiology*  
Iv, M. n., Samghabadi, P. n., Holdsworth, S. n., Gentles, A. n., Rezaii, P. n., Harsh, G. n., Li, G. n., Thomas, R. n., Moseley, M. n., Daldrup-Link, H. E., Vogel, H. n., Wintermark, M. n., Cheshier, et al  
2018: 181204
- **Conditional Probability of Survival as a Proposed Endpoint for Future Single-Arm Clinical Trials in Glioblastoma**  
Patel, C. B., Thomas, R. P., Nagpal, S., Recht, L. D.  
WILEY.2017: S206–S207
- **Anti-PD-1-associated inflammatory-demyelinating lesions in patients with brain metastases**  
Samghabadi, P., Makar, S., Thomas, R., Pelpola, J., Reddy, S., Tranvinh, E., Spence, A., Vogel, H., Born, D., Sobel, R.  
OXFORD UNIV PRESS INC.2017: 500–501
- **Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.** *International journal of radiation oncology, biology, physics*  
Pollom, E. L., Fujimoto, D., Wynne, J., Seiger, K., Modlin, L. A., Jacobs, L. R., Azoulay, M., von Eyben, R., Tupper, L., Gibbs, I. C., Hancock, S. L., Li, G., Chang, et al  
2017; 98 (1): 123-130
- **Response of metastatic glioma to vemurafenib.** *Neuro-oncology practice*  
Leaver, K. E., Zhang, N., Ziskin, J. L., Vogel, H., Recht, L., Thomas, R. P.  
2016; 3 (4): 268-271
- **Melanoma central nervous system metastases: current approaches, challenges, and opportunities** *PIGMENT CELL & MELANOMA RESEARCH*  
Cohen, J. V., Tawbi, H., Margolin, K. A., Amravadi, R., Bosenberg, M., Brastianos, P. K., Chiang, V. L., de Groot, J., Glitza, I. C., Herlyn, M., Holmen, S. L., Jilaveanu, L. B., Lassman, et al  
2016; 29 (6): 627-642
- **Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma** *JOURNAL OF NEURO-ONCOLOGY*  
Nagpal, S., Recht, C. K., Bertrand, S., Thomas, R. P., Ajlan, A., Pena, J., Gershon, M., Coffey, G., Kunz, P. L., Li, G., Recht, L. D.  
2015; 123 (2): 277-282
- **Treatment options for optic pathway gliomas.** *Current treatment options in neurology*  
Thomas, R. P., Gibbs, I. C., Xu, L. W., Recht, L.  
2015; 17 (2): 333-?
- **Treatment Options for Optic Pathway Gliomas** *CURRENT TREATMENT OPTIONS IN NEUROLOGY*  
Thomas, R. P., Gibbs, I. C., Xu, L. W., Recht, L.  
2015; 17 (2)
- **ARE WE USING TOO MUCH BEVACIZUMAB IN OUR GBM PATIENTS?**  
Ajlan, A., Thomas, P., Thomas, R., Nagpal, S., Recht, L.  
OXFORD UNIV PRESS INC.2014
- **COMPLETE RESPONSE TO VEMURAFINIB IN A PATIENT WITH METASTATIC ANAPLASTIC XANTHROASTROCYTOMA**  
Thomas, R., Ajlan, A., Ziskin, J., Soltys, S., Reddy, S., Recht, L., Nagpal, S.  
OXFORD UNIV PRESS INC.2014
- **Simultaneous perfusion and permeability measurements using combined spin- and gradient-echo MRI.** *Journal of cerebral blood flow and metabolism*  
Schmiedeskamp, H., Andre, J. B., Straka, M., Christen, T., Nagpal, S., Recht, L., Thomas, R. P., Zaharchuk, G., Bammer, R.  
2013; 33 (5): 732-743

- **The incidence and significance of multiple lesions in glioblastoma** *JOURNAL OF NEURO-ONCOLOGY*  
Thomas, R. P., Xu, L. W., Lober, R. M., Li, G., Nagpal, S.  
2013; 112 (1): 91-97
- **Advances in the management of glioblastoma: the role of temozolomide and MGMT testing.** *Clinical pharmacology : advances and applications*  
Thomas, R. P., Recht, L., Nagpal, S.  
2013; 5: 1-9
- **PRELIMINARY RESULTS UTILIZING VESSEL SIZE IMAGING AS A METRIC OF RESPONSE IN GLIOBLASTOMA MULTIFORME** *17th Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology (SNO)*  
Andre, J. B., Schmiedeskamp, H., Thomas, R. P., Feroze, A., Nagpal, S., Zaharchuk, G., Straka, M., Recht, L., Bammer, R.  
OXFORD UNIV PRESS INC.2012: 127-127
- **THE INCIDENCE AND SIGNIFICANCE OF MULTIPLE LESIONS IN GLIOBLASTOMA**  
Xu, L. W., Thomas, R. P., Lober, R. M., Nagpal, S., Li, G.  
OXFORD UNIV PRESS INC.2012: 120
- **Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells** *JOURNAL OF IMMUNOLOGY*  
Brown, C. E., Vishwanath, R. P., Aguilar, B., Starr, R., Najbauer, J., Aboody, K. S., Jensen, M. C.  
2007; 179 (5): 3332-3341
- **A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells** *JOURNAL OF IMMUNOLOGICAL METHODS*  
Vishwanath, R. P., Brown, C. E., Wagner, J. R., Meechoovet, H. B., Naranjo, A., Wright, C. L., Olivares, S., Qian, D., Cooper, L. J., Jensen, M. C.  
2005; 302 (1-2): 78-89
- **Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing** *JOURNAL OF IMMUNOLOGICAL METHODS*  
Brown, C. E., Wright, C. L., Naranjo, A., Vishwanath, R. P., Chang, W. C., Olivares, S., Wagner, J. R., Bruins, L., Raubitschek, A., Cooper, L. J., Jensen, M. C.  
2005; 297 (1-2): 39-52
- **Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products** *JOURNAL OF CLINICAL LABORATORY ANALYSIS*  
Juhasz, A., Frankel, P., Cheng, C., Rivera, H., Vishwanath, R., Chiu, A., Margolin, K., Yen, Y., Newman, E. M., Synold, T., Wilczynski, S., Lenz, H. J., Gandara, et al  
2003; 17 (5): 184-194